Jalili, H. | Search bioRxiv

bioRxiv2023

AI-Driven Insights into the complexities of Chinese hamster ovary cells death in order to optimize production processes.

Chinese hamster ovary (CHO) cells are a multipurpose and high-performance cell line for recombinant protein production in biopharmaceutical industry. They have proven their ability to produce a wide range of therapeutic proteins with high efficiency and quality. Designing novel and high-performance CHO cell lines has an incredible impact in biopharmaceutical industry that can reduce prices and increase product efficiency. One of the best ways is to prevent CHO cells death during Bioprocessing. Apoptosis is the most common form of CHO cells death during Bioprocessing. Analyzing Apoptosis and cell-cycle complex signaling pathways are necessary for the control of cell growth, efficiency, and the death of CHO cells. Therefore, analyzing and understanding interactions of these pathways and their interactions with other cellular processes can help optimize the performance and quality of CHO cell lines. AI-driven insight solutions and Advanced machine learning algorithms like GAT (Graph Attention Network) used in this project indicate most important Targets in complex signaling pathways. Pathways such as the TNF signaling pathway, and also viruses like: Hepatitis C, HIV1 and Bacteria like: Salmonella have High intersection size and Low P-value with complex signaling pathways. These microorganisms should be used to design high-performance CHO cell lines because they are master in these pathways. This method can be used to find novel and high efficiency targets for curing cancer in humans.

bioinformatics↗

bioRxiv2022

Omicron-Based Vaccine Candidate Elicits Potent Neutralizing Antibodies in the Animal Model

BackgroundOmicron variant (B. 1.1.529) is able to escape from naturally acquired and vaccine-induced immunity, which mandates updating the current COVID-19 vaccines. Here, we investigated and compared the neutralising antibody induction of the ancestral variant-based BIV1-CovIran vaccine, the Omicron variant-based BIV1-CovIran Plus vaccine, and the novel bivalent vaccine candidate, BBIV1-CovIran, against the Omicron and ancestral Wuhan variants on the rat model. MethodsViruses were isolated from a clinical specimen and virus characterisation performed. After inactivating the viral particles, the viruses were purified and formulated. Bivalent vaccines were a composition of 2.5 g (5 g total) or 5 g (10 g total) doses of each ansectral-based and Omicron-based monovalent vaccine. Subsequently, the potency of the monovalent and bivalent vaccines was investigated using the virus neutralisation test (VNT). ResultsThe group that received three doses of the Omicron-specific vaccine demonstrated neutralisation activity against the Omicron variant with a geometric mean titer of 337.8. However, three doses of the Wuhan variant-specific vaccine could neutralise the Omicron variant at a maximum of 1/32 serum dilution. The neutralisation activity of the Omicron-specific vaccine, when administered as the booster dose after two doses of the Wuhan variant-specific vaccine, was 100% against the Omicron variant and the Wuhan variant at 1/64 and 1/128 serum dilution, respectively. Three doses of 5 g bivalent vaccine could effectively neutralise both variants at the minimum of 1/128 serum dilution. The 10 g bivalent vaccine at three doses showed even higher neutralisation titers: geometric mean titer of 338.0 against Omicron and 445.7 against Wuhan). ConclusionIt is shown that the candidate bivalent vaccine could elicit a potent immune response against both Wuhan-Hu-1 and Omicron BA.1 variants. Therefore, we plan to evaluate the updated vaccine in the clinical trial setting.

immunology↗